Last updated on September 2018

Study of REGN2810 and REGN1979 in Patients With Lymphoma

Brief description of study

This is an open-label, multicenter, dose escalation study of REGN2810 and REGN1979 in patients with lymphoma. The study treatment period will be from 6 to 12 months, depending on how an individual patient responds to treatment. The follow-up period will be 6 months for all patients.

Clinical Study Identifier: NCT02651662

Contact Investigators or Research Sites near you

Start Over

Clinical Trials Administrator

Regeneron Research Facility
Jena, Germany
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.